trending Market Intelligence /marketintelligence/en/news-insights/trending/eth2EIkXjPLeWHXlHvNGvA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Exonate, J&J collaborating to develop eye disease treatment

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Exonate, J&J collaborating to develop eye disease treatment

Exonate Ltd and Johnson & Johnson entered into a collaboration agreement to develop an eye drop treatment for certain eye diseases.

Under the collaboration agreement, signed between Exonate and J&J's Janssen Pharmaceuticals Inc., the companies will develop an eye drop treatment for retinal vascular diseases such as wet age-related macular degeneration, or wet AMD, and diabetic macular oedema, or DMO, by using mRNA targeted therapies.

Wet AMD develops when abnormal blood vessels grow into the region of the retina called the macula, which leaks blood or fluid resulting in scarring of the macula and rapid loss of central vision. DMO is the build of fluid in the macula resulting in loss of vision.

Additional terms of the agreement were not disclosed in a Jan. 13 news release.

U.K.-based Exonate is a private biotechnology company that specializes in the discovery and development of small molecule drugs that modulate alternative mRNA splicing.